<DOC>
	<DOCNO>NCT00506077</DOCNO>
	<brief_summary>The purpose study determine safety effectiveness investigational drug MK0249 treatment cognitive impairment patient schizophrenia .</brief_summary>
	<brief_title>MK0249 Treatment Cognitive Impairment Patients With Schizophrenia ( 0249-016 )</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Schizophrenia , Paranoid</mesh_term>
	<criteria>Patient clinically stable , current antipsychotic medication least 3 month current dose 2 month Patient 6th grade read level well Females pregnant , child agree remain abstinent use acceptable birth control throughout study Patient stable living arrangement least 3 month prior study start Patient general good health base screen assessment Patient total Positive Negative Syndrome Scale ( PANSS ) score 36 75 screening first baseline visit Patient Clinical Global Impressions Severity ( CGIS ) score less equal 4 screen first baseline visit Patient major disease/disorder may interfere cognitive testing ( mental retardation ) and/or pose risk upon study participation Patient history head trauma loss consciousness great 15 minute Patient warfarin treatment , MAO inhibitor , clonazepam clozapine within 1 month screen Patient ECT treatment within 6 month screen Patient require treatment antihistamine certain medication list protocol Patient history liver disease active within last 2 year , history cancer within past 5 year Patient history alcohol drug dependence within past year alcohol drug abuse within 3 month screen</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Undifferentiated schizophrenia</keyword>
	<keyword>residual schizophrenia</keyword>
</DOC>